Abstract

Tufts University School of Medicine/New England Medical Center (Tufts- NEMC) has served as an active main institution for the Eastern Cooperative Oncology for 35 years. During that time, the network has enrolled over 6,600 patients on NCI sponsored clinical trials and made a number of scientific contributions to ECOG. The combination of network accrual and scientific contribution has made Tufts-NEMC one of the most active clinical trials programs in ECOG and in the United States. This grant requests continued support for Tufts-NEMC to continue its mission as a main ECOG institution, supporting NCI sponsored cancer clinical trials throughout New England. The Tufts-NEMC ECOG network currently includes 19 hospitals in 4 New England States: Massachusetts, Connecticut, Maine, and Rhode Island. We are requesting salary support for the Principal Investigator, scientific study chairs, data managers and coordinators. Funds will support travel to and from ECOG meetings and will be used to enhance electronic communications and data management across a broad geographic region. Funds will also support information storage and transmission in the network, since the addition of other sites and investigators in the region is likely during the period of this grant.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA007190-36
Application #
2828992
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1982-12-01
Project End
2004-04-30
Budget Start
1999-08-16
Budget End
2000-04-30
Support Year
36
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
Tufts University
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02111

  Publications

Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Ganz, Patricia A; Land, Stephanie R; Geyer Jr, Charles E et al. (2011) Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29:1110-6
Swain, Sandra M; Jeong, Jong-Hyeon; Geyer Jr, Charles E et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-65
Landry, Jerome; Catalano, Paul J; Staley, Charles et al. (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587-92
Hughes, Lorie L; Wang, Molin; Page, David L et al. (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:5319-24
Horn, Leora; Dahlberg, Suzanne E; Sandler, Alan B et al. (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-11
Greenberg, Peter L; Sun, Zhuoxin; Miller, Kenneth B et al. (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393-400
Souphron, Judith; Waddell, M Brett; Paydar, Amir et al. (2008) Structural dissection of a gating mechanism preventing misactivation of ubiquitin by NEDD8's E1. Biochemistry 47:8961-9
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53

Showing the most recent 10 out of 30 publications